In pursuit of this goal, a variety of potential biomarkers have been investigated to assess the efficacy of ICIs across different cancer types, including tumor-infiltrating lymphocytes, programmed cell death ligand (PD-L1) expression, and tumor mutational burden (TMB) [9,10]. The gene discussed is CD274; the disease is neoplasm.